Old Well Partners’s iTeos Therapeutics ITOS Stock Holding History

Old Well Partners’s Portfolio ITOS Stock Details ITOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-5,096	Closed	-$237K	–	38
2021 Q4	$237K	Buy	+5,096	New	+$170K	0.15%	27

Other funds holding ITOS

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Old Well Partners's ITOS Position: Q1 2022 in Review

Old Well Partners sold out of iTeos Therapeutics (ITOS) in Q1 2022, closing a stake of 5,096 shares — an estimated $237K sold.

Old Well Partners first reported a position in ITOS in Q4 2021 and held it in 1 quarter. The position peaked at $237K in Q4 2021. 159 funds tracked by Wall St. Rank hold ITOS as of Q1 2022.

Old Well Partners reported no remaining iTeos Therapeutics position as of Q1 2022 after selling out during the quarter.
Old Well Partners sold 5,096 iTeos Therapeutics shares in Q1 2022, an estimated $237K.
Old Well Partners first reported a position in iTeos Therapeutics in Q4 2021 and held it in 1 quarter.
Old Well Partners's iTeos Therapeutics position peaked at $237K in Q4 2021.
159 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q1 2022.

Based on Old Well Partners's 13F filing for Q1 2022, filed 16 May 2022.